BioMimetic's Pipeline Progresses - Analyst Blog
January 04 2013 - 1:16PM
Zacks
Biotechnology company, BioMimetic Therapeutics,
Inc. (BMTI) recently announced that it has started
enrolling patients for a phase II trial of its candidate, Augment
Chronic Tendinopathy (ACT) for the treatment of lateral
epicondylitis (tennis elbow). ACT is based on recombinant human
platelet-derived growth factor. The company expects to complete the
enrollment process by the end of this year.
The company intends to enroll up to 100 patients in this
randomized, escalating dose, double-blinded, placebo controlled and
multi-center phase II trial. The trial will evaluate the safety and
efficacy profile of ACT ascending doses. In the trial patients,
aged between 21 and 80 years will receive one injection of either
placebo or any of the four different doses of ACT into the extensor
carpi radialis brevis (ECRB).
The efficacy of the candidate will be measured on the basis of
visual analog scale (VAS), disabilities of the arm, shoulder and
hand (DASH) score and the patient rated tennis elbow evaluation
(PRTEE) and grip strength testing.
In November 2012, BioMimetic entered into an agreement with Wright
Medical Group, Inc. to combine both the businesses. We believe that
the BioMimetic’s biologics pipeline will complement Wright’s
product portfolio. The deal is expected to close in the first
quarter of 2013, subject to approval by BioMimetic
shareholders.
We currently have a Neutral recommendation on Biomimetic
Therapeutics Inc. The stock carries a Zacks #1 Rank (Strong Buy) in
the short run.
Other Zacks #1 Rank stocks include Amgen Inc.
(AMGN), Repligen Corporation (RGEN) and
Targacept Inc. (TRGT).
AMGEN INC (AMGN): Free Stock Analysis Report
BIOMIMETIC THER (BMTI): Free Stock Analysis Report
REPLIGEN (RGEN): Free Stock Analysis Report
TARGACEPT INC (TRGT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Biomimetic Therapeutics, Inc. (MM) (NASDAQ:BMTI)
Historical Stock Chart
From Apr 2024 to May 2024
Biomimetic Therapeutics, Inc. (MM) (NASDAQ:BMTI)
Historical Stock Chart
From May 2023 to May 2024